Abstract
Skeletal muscle abnormalities, including sarcopenia, are commonly seen in patients with moderate to advanced chronic kidney disease (CKD). Patients with CKD and coexisting sarcopenia have increased mortality along with decreased quality of life, increased frailty scores, and reduced physical functionality. The pathogenesis of CKD-associated sarcopenia is complex and multifactorial, leading to great interest in understanding this disease process.1 Such advances would eventually lead to the discovery of novel targeted therapies for CKD-associated muscle wasting that could potentially improve the quality of life of substantial numbers of patients.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
